Loading
breast cancer
People whose work centres on breast cancer. 21 records carry it: 21 people. Also written “breast-cancer”; the spellings share this page.
Related tags
21 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Anna Sapino Scientific Director · Istituto di Candiolo IRCCS (FPO) Pathologist and Scientific Director of the Candiolo Cancer Institute (INOC), Piedmont's oncology IRCCS and an OECI-certified Comprehensive Cancer Centre. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer | none | leadership, clinician-scientist, pathology | ||
Christian Singer Vice-President · Austrian Breast & Colorectal Cancer Study Group Gynaecological oncologist at the Medical University of Vienna and ABCSG Vice-President, known for work on breast cancer and hereditary cancer risk. | HR-positive / HER2-negative breast cancer, Ovarian cancer | none | leadership, clinician-scientist, hereditary cancer | ||
Daniela Dornelles Rosa Medical oncologist; Hospital Moinhos de Vento, Hospital de Clínicas de Porto Alegre and Universidade Federal do Rio Grande do Sul (2026 paper affiliations); breast cancer investigator with GBECAM and LACOG · Hospital de Clínicas de Porto Alegre A breast cancer oncologist in Porto Alegre who led the AMAZONA III study, which measured how much later Brazilian women in the public health system are diagnosed and treated than women with private insurance. | HR-positive / HER2-negative breast cancer | none | clinician-scientist | ||
Donna McKay President & CEO · Breast Cancer Research Foundation President and CEO of the Breast Cancer Research Foundation, the largest private funder of breast cancer research worldwide. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer | none | leadership, research funding | ||
Dorraya El-Ashry Chief Scientific Officer · Breast Cancer Research Foundation Breast cancer biologist and Chief Scientific Officer of the Breast Cancer Research Foundation, directing its global research grant portfolio. | HR-positive / HER2-negative breast cancer, Triple-negative breast cancer | none | leadership, clinician-scientist | ||
Eva Ciruelos Vice President (Vicepresidenta) · SOLTI Cancer Research Group Madrid breast oncologist and Vice President of the SOLTI breast cancer research group. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer | none | leadership, clinician-scientist | ||
Giovanni Blandino Scientific Director, IRCCS Regina Elena National Cancer Institute · IRCCS Regina Elena National Cancer Institute Molecular oncologist known for mutant p53 research, appointed Scientific Director of Rome's Regina Elena National Cancer Institute in 2026. | Triple-negative breast cancer, Head and neck squamous cell carcinoma | none | leadership, clinician-scientist, molecular oncology | ||
Isabel T. Rubio Past-President · European Society of Surgical Oncology Breast surgeon and ESSO Past-President who heads breast surgical oncology at Clínica Universidad de Navarra in Madrid. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer | none | leadership, clinician-scientist, surgical oncology | ||
Jason Carroll Interim Director · Cancer Research UK Cambridge Centre / CRUK Cambridge Institute Molecular oncologist and Interim Director of the Cancer Research UK Cambridge Institute, known for mapping how the oestrogen receptor drives breast cancer. | HR-positive / HER2-negative breast cancer | none | leadership, clinician-scientist, basic science | ||
Mafalda Oliveira President (Presidenta) · SOLTI Cancer Research Group Barcelona breast oncologist who leads SOLTI, the Spanish academic breast cancer research group, and co-authors pivotal endocrine therapy trials. | HR-positive / HER2-negative breast cancer | none | leadership, clinician-scientist, clinical trials | ||
Marek Svoboda General Director · Masaryk Memorial Cancer Institute Medical oncologist who leads the Masaryk Memorial Cancer Institute in Brno, the Czech Republic's largest dedicated cancer centre. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer | none | leadership, clinician-scientist, medical oncology | ||
Michael Gnant President · Austrian Breast & Colorectal Cancer Study Group Viennese surgical oncologist who presides over the ABCSG and has led landmark adjuvant breast cancer trials such as ABCSG-12, ABCSG-18 and PALLAS. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer | none | leadership, clinician-scientist, clinical trials | ||
Nikolaus Rajewsky Group Leader, Systems Biology of Gene Regulatory Elements; Scientific Director, Berlin Institute for Medical Systems Biology (MDC-BIMSB) · Max Delbrück Center for Molecular Medicine Systems biologist at the MDC known for microRNA and circular RNA discoveries and for single-cell and spatial genomics applied to cancer. | Triple-negative breast cancer, Non-small-cell lung cancer, Neuroblastoma | none | clinician-scientist, systems biology, genomics | ||
Norman Wolmark Chairman · NSABP Foundation Surgical oncologist and long-time Chairman of the NSABP, whose trials established breast-conserving surgery and adjuvant therapy standards in breast and colorectal cancer. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Colorectal cancer | none | leadership, clinician-scientist, clinical trials | ||
Priya Rastogi Chief Executive Officer & Medical Director · NSABP Foundation Pittsburgh medical oncologist who serves as CEO and Medical Director of the NSABP Foundation, leading its breast cancer trial portfolio. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer | none | leadership, clinician-scientist, clinical trials | ||
Rebecca Dent Deputy Chief Executive Officer (Clinical) · National Cancer Centre Singapore Breast medical oncologist and Deputy CEO for clinical operations at the National Cancer Centre Singapore, an international leader in triple-negative breast cancer trials. | Triple-negative breast cancer, HR-positive / HER2-negative breast cancer, HER2-positive breast cancer | none | leadership, clinician-scientist | ||
Sara Y. Brucker Deputy Speaker; Medical Director, Department for Women's Health · Comprehensive Cancer Center Tübingen-Stuttgart Gynaecologist who co-leads the CCC Tübingen-Stuttgart and directs women's health at Tübingen University Hospital, with research in breast and gynaecological cancers. | HR-positive / HER2-negative breast cancer, Endometrial cancer, Ovarian cancer | none | leadership, clinician-scientist, gynaecological oncology | ||
Sunil Lakhani Chair of the Board · Breast Cancer Trials Brisbane breast pathologist who chairs the board of Breast Cancer Trials, the Australia and New Zealand breast cancer clinical trials group. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer | none | leadership, clinician-scientist, pathology | ||
Susan Clark Head of the Cancer Epigenetics Laboratory · Garvan Institute of Medical Research / Kinghorn Cancer Centre Pioneer of DNA methylation analysis whose Garvan laboratory studies how epigenetic changes drive prostate and breast cancer. | Prostate cancer, HR-positive / HER2-negative breast cancer | none | clinician-scientist, epigenetics, prostate cancer | ||
Suzette Delaloge Chair of the Board of Directors · Institut National du Cancer Breast medical oncologist from Gustave Roussy who chairs the board of France's Institut National du Cancer. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer | none | leadership, clinician-scientist, cancer policy | ||
Tari A. King President-Elect · Society of Surgical Oncology Breast surgical oncologist at Winship Cancer Institute and President-Elect of the Society of Surgical Oncology, known for research on lobular breast cancer and surgical de-escalation. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer | none | leadership, clinician-scientist, surgical oncology |
